Advertisement

Advertisement
Issues in Oncology

How Hepatitis C Virus Screening May Improve Survival in Patients With Cancer

In 2013, the Centers for Disease Control and Prevention (CDC) and the U.S. Preventive Services Task Force (USPSTF) recommended that all people born between 1945 and 1965...

Lung Cancer

Long-Term Results With Local Consolidative Therapy vs Maintenance Therapy or Observation in Oligometastatic NSCLC

In long-term follow-up of a phase II study reported in the Journal of Clinical Oncology, Gomez et al confirmed superior outcomes with local consolidative therapy...

Issues in Oncology
Cost of Care

Psychosocial Care Is a Critical Component of Value-Based Oncology

The ongoing dialogue regarding health-care payment reform that attempts to incentivize high-value care by linking reimbursement to quality rather than quantity...


Advertisement
Gastrointestinal Cancer
Breast Cancer

Trastuzumab Deruxtecan in Advanced HER2-Positive Gastric and Breast Cancers

Two phase I studies reported in The Lancet Oncology indicate activity of the antibody-drug conjugate trastuzumab deruxtecan in advanced...

Survivorship

Risk of Cardiomyopathy in Childhood Cancer Survivors

In a study reported in JAMA OncologyEric J. Chow, MD, MPH, and colleagues found that daunorubicin was associated with decreased cardiomyopathy risk...

Advertisement




More Top Stories

Prostate Cancer

James L. Mohler, MD, on Managing Prostate Cancer: NCCN Guidelines Updates

Issues in Oncology

Psychosocial Care Is a Critical Component of Value-Based Oncology

The ongoing dialogue regarding health-care payment reform that attempts to incentivize high-value care by linking reimbursement to quality rather than quantity has largely ignored the ultimate consumer/buyer—the patient. Yet, in the minds of clinicians, policymakers, and the public at large,...

Advertisement

TRINOVA-3: Addition of Trebananib to Carboplatin/Paclitaxel as First-Line Treatment for Advanced Ovarian Cancer

In a phase III trial (TRINOVA-3/ENGOT-ov2/GOG-3001) reported in The Lancet Oncology, Vergote et al found that addition of the antiangiogenic agent trebananib to carboplatin/paclitaxel did not improve progression-free survival in first-line treatment of advanced ovarian cancer. Trebananib is a...

Lung Cancer

Susan Y. Wu, MD, on Non–Small Cell Lung Cancer: Using an Online Tool in Treatment

Solid Tumors
Bladder Cancer

FDA Grants Accelerated Approval to Erdafitinib for Metastatic Urothelial Carcinoma

On April 15, the U.S. Food and Drug Administration (FDA) granted accelerated approval to erdafitinib (Balversa) for patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations that has progressed during or following platinum-containing...

Mark E. Thompson, MD, Named Medical Director for Public Policy at Community Oncology Alliance

The Community Oncology Alliance (COA) recently announced that Mark E. Thompson, MD, has been appointed to the newly created staff position of Medical Director for Public Policy. Dr. Thompson will chair the COA Government Affairs and Policy Committee, a standing committee that guides official...

American Cancer Society Sets 2035 Cancer Mortality Reduction Goal

The American Cancer Society (ACS) has set a challenge goal to reduce overall cancer mortality 40% between 2015 and 2035—a goal set by applying favorable cancer mortality trends among college graduates to the population as a whole. A report on the goal was published by Ma et al in CA: A...

Immunotherapy
Leukemia
Lymphoma

Frederick L. Locke, MD, on Innovative CAR-T Cell Therapies: The Patient Experience

ASCO Launches FY 2020 Advocacy Campaign for Federally Funded Cancer Research

ASCO HAS KICKED OFF its Fiscal Year (FY) 2020 advocacy campaign in support of increased funding for federal cancer research. ASCO is urging Congress to provide $41.6 billion to the National Institutes of Health (NIH)—a $2.5 billion increase from FY 2019— and $6.5 billion to the National Cancer...

Advertisement

ASTRO and AUA Announce Updates to Joint Clinical Guidance for Adjuvant and Salvage Radiotherapy After Prostatectomy

The American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA) recently announced updates to their joint clinical guideline on adjuvant and salvage radiotherapy after prostatectomy in patients with and without evidence of prostate cancer recurrence to include new...